




## Zafirlukast

Revised: May 1, 2019.

CASRN: 107753-78-6



## Drug Levels and Effects

### Summary of Use during Lactation

No published information is available on the use of zafirlukast during breastfeeding; however, manufacturer's data indicate that the dose in milk is low. If zafirlukast is required by the mother, it is not a reason to discontinue breastfeeding. However, an alternate drug may be preferred, especially while nursing a newborn or preterm infant. Zafirlukast has been used in children as young as 12 months of age.[1]

### Drug Levels

*Maternal Levels.* Relevant published information was not found as of the revision date.

The manufacturer reports that after administration of zafirlukast 40 mg twice daily to lactating women (number not reported), average steady-state milk concentrations were 50 mcg/L.[2] Using these data, a fully breastfed infant would be expected to receive about 0.6% of the maternal weight-adjusted dosage.

*Infant Levels.* Relevant published information was not found as of the revision date.

## Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

## Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

## Alternate Drugs to Consider

Beclomethasone, Cromolyn, Montelukast, Terbutaline, Theophylline

## References

1. Berlin CM, Briggs GG. Drugs and chemicals in human milk. *Semin Fetal Neonatal Med.* 2005;10:149-59. PubMed PMID: 15701580.
2. Anon. Accolate Package Insert. AstraZeneca Pharmaceuticals. Wilmington DE. 2011.

## Substance Identification

### Substance Name

Zafirlukast

### CAS Registry Number

107753-78-6

### Drug Class

Breast Feeding

Lactation

Anti-Asthmatic Agents

Leukotriene Antagonists